Table 3. Laboratory examination and clinical treatment.
| Variables | CR group (n=195) | Control group (n=390) | P value |
|---|---|---|---|
| Laboratory tests | |||
| WBC (×109/L) | 11.85±4.49 | 9.89±3.17 | <0.001 |
| Neutrophils (×109/L) | 9.39±4.26 | 7.44±3.18 | <0.001 |
| Absolute lymphocyte counts (×109/L) | 1.39±0.70 | 1.46±0.60 | 0.190 |
| Hemoglobin (g/L) | 128.48±17.97 | 134.55±17.96 | <0.001 |
| Platelet count (×109/L) | 228.24±65.76 | 224.06±62.77 | 0.455 |
| CK (U/L) | 1,109.00 (517.00, 1,958.00) | 783.50 (273.25, 1,488.50) | <0.001 |
| CK-MB (U/L) | 109.32 (50.00, 220.57) | 73.10 (32.00, 151.85) | <0.001 |
| Ccr (µmol/L) | 90.46±52.27 | 85.28±26.56 | 0.194 |
| TG (mmol/L) | 1.48±0.92 | 1.58±0.81 | 0.176 |
| TC (mmol/L) | 4.51±0.92 | 4.58±0.98 | 0.404 |
| HDL-C (mmol/L) | 1.09±0.27 | 1.06±0.27 | 0.287 |
| LDL-C (mmol/L) | 2.84±0.76 | 2.98±0.86 | 0.062 |
| NT-proBNP (pg/mL) | 3,606.00 (1,184.00, 7,750.81) | 1,147.50 (353.15, 2,648.00) | <0.001 |
| LVEF | 43.93±9.83 | 49.92±8.85 | <0.001 |
| Clinical treatment, n (%) | |||
| PCI | 66 (33.8) | 132 (33.8) | 1.000 |
| Thrombolysis | 8 (4.1) | 19 (4.9) | 0.676 |
| DAPT | 190 (97.4) | 386 (99.0) | 0.168 |
| β-blocker | 123 (63.1) | 277 (71.0) | 0.051 |
| ACEI/ARB | 120 (61.5) | 260 (66.7) | 0.220 |
| Diuretics | 107 (54.9) | 118 (30.3) | <0.001 |
| Positive inotropic drugs | 52 (26.7) | 50 (12.8) | <0.001 |
CR, cardiac rupture; WBC, white blood cells; CK, creatine kinase; CK-MB, creatine kinase-MB; Ccr, chemokine receptor; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, amino-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; DAPT, dual antiplatelet therapy; ACEI/ARB, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.